Polypharmacy
Conditions
Interventions
Group 1: Test group: digitally supported pharmacotherapy decisions considering the pharmacogenetic profiles of patients. The treating physicians are provided with the PGXperts PGx profile. The physici
Sponsors
PGXperts GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients from general practices who take more than four medications. 2. Willingness to provide a blood sample for molecular genetic laboratory testing. 3. Patients with possible medication-related issues, such as adverse drug reactions, side effects, lack of efficacy, or non-specific symptoms, in whom the treating physician considers a review of the overall medication to be necessary.
Exclusion criteria
Exclusion criteria: 1. Bone marrow, liver or kidney transplant. 2. Blood transfusion in the last four weeks. 3. Cognitive impairment that causes the investigator to consider the patient unsuitable for inclusion in the study. 4. Cancer treated with chemotherapy within the last five years. 5. Insufficient knowledge of German, such that the patient cannot, in the opinion of the investigator, communicate sufficiently. 6. Acute onset of symptoms without any recognisable connection to the medication. 7. Acute or subacute symptoms requiring immediate adjustment of medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in EQ-5D-VAS score at week 4 compared to baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| - Difference from baseline in the EQ-5D-5L index after week 4 - Difference from baseline in the symptom total score (SSS) after four weeks. | — |
Countries
Germany
Contacts
Public ContactPaola Zambrano
PGXperts GmbH
Outcome results
None listed